Keytruda and Encephalopathy - a phase IV clinical study of FDA data
Summary:
Encephalopathy is reported as a side effect among people who take Keytruda (pembrolizumab), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Carboplatin, and have Lung neoplasm malignant.
The phase IV clinical study analyzes which people have Encephalopathy when taking Keytruda. It is created by eHealthMe based on reports of 57,304 people who have side effects when taking Keytruda from the FDA, and is updated regularly.
What is Keytruda?
Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.
What is Encephalopathy?
Encephalopathy (functioning of the brain is affected by some agent or condition) is found to be associated with 1,459 drugs and 1,608 conditions by eHealthMe. Check the latest studies of Encephalopathy.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
57,304 people reported to have side effects when taking Keytruda.
Among them, 92 people (0.16%) have Encephalopathy.

Among these 92 people:
How long have people been on Keytruda when they have Encephalopathy? *
- < 1 month: 48.65 %
- 1 - 6 months: 27.03 %
- 6 - 12 months: 21.62 %
- 1 - 2 years: 2.7 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
What is the gender of people who have Encephalopathy when taking Keytruda? *
- female: 40.23 %
- male: 59.77 %
What is the age of people who have Encephalopathy when taking Keytruda? *
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 0.0 %
- 30-39: 1.59 %
- 40-49: 1.59 %
- 50-59: 19.05 %
- 60+: 77.78 %
What are other drugs people take besides Keytruda? *
- Pemetrexed: 10 people, 10.87%
- Nebivolol Hydrochloride: 10 people, 10.87%
- Carboplatin: 10 people, 10.87%
- Lenvima: 4 people, 4.35%
- Pantoprazole: 3 people, 3.26%
- Axitinib: 3 people, 3.26%
- Tylenol: 2 people, 2.17%
- Amlodipine: 2 people, 2.17%
- Lasix: 2 people, 2.17%
- Micardis: 2 people, 2.17%
What are other side effects people have besides Encephalopathy? *
- Confusional State: 12 people, 13.04%
- Malignant Neoplasm Progression (cancer tumour came back): 10 people, 10.87%
- Circulatory Collapse: 9 people, 9.78%
- Encephalitis (inflammation of the brain): 8 people, 8.70%
- Fever: 8 people, 8.70%
- Weakness: 8 people, 8.70%
- Diarrhea: 6 people, 6.52%
- High Blood Pressure: 5 people, 5.43%
- Pneumonia: 5 people, 5.43%
- Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 5.43%
What are the existing conditions these people have? *
- Lung Neoplasm Malignant (cancer tumour of lung): 14 people, 15.22%
- Lung Cancer - Non-Small Cell (lung cancer): 9 people, 9.78%
- Endometrial Cancer: 6 people, 6.52%
- Lung Adenocarcinoma (a form of non-small cell lung cancer): 6 people, 6.52%
- Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 5 people, 5.43%
- Malignant Melanoma (skin cancer rises from melancytes): 5 people, 5.43%
- High Blood Pressure: 4 people, 4.35%
- Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 3 people, 3.26%
- Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 2 people, 2.17%
- Colon Cancer Stage Iv: 2 people, 2.17%
* Approximation only. Some reports may have incomplete information.
Do you take Keytruda and have Encephalopathy?
- Check whether Encephalopathy is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, long term effects of, and alternative drugs to Keytruda:
- Keytruda (57,404 reports)
Encephalopathy treatments and more:
- Encephalopathy (27,832 reports)
How severe was Encephalopathy and when was it recovered:
Expand to all the drugs that have ingredients of pembrolizumab:
Sub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Keytruda:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all the drugs that are associated with Encephalopathy:
- Encephalopathy (1,459 drugs)
Browse all the conditions that are associated with Encephalopathy:
- Encephalopathy (1,608 conditions)
Related publications that referenced our studies
- Kapoor A, Kumar V, Beniwal S, Dutta S, Goyal S, Kumar HS, "Posterior reversible encephalopathy syndrome in non-Hodgkin's lymphoma: Not necessarily reversible!", Clinical Cancer Investigation Journal, 2015 Mar .
- Kapoor A, Kumar V, Beniwal S, Dutta S, Goyal S, Kumar HS, "Posterior reversible encephalopathy syndrome in non-Hodgkin's lymphoma: Not necessarily reversible!", Clinical Cancer Investigation Journal, 2015 Mar .
How the study uses the data?
The study uses data from the FDA. It is based on pembrolizumab (the active ingredients of Keytruda) and Keytruda (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Could Valsartan cause Cardiac Failure? - a second ago
- Could Valsartan cause General Physical Health Deterioration? - 14 seconds ago
- Could Amoxicillin cause Wheezing? - 18 seconds ago
- Could Medroxyprogesterone Acetate cause Thrombosis? - 24 seconds ago
- Could Astragalus cause Weight Increased? - 26 seconds ago
- Could Valsartan cause Gastrointestinal Haemorrhage? - 29 seconds ago
- Could Pantoprazole cause Rosacea? - 29 seconds ago
- Could Hydroxyzine Hydrochloride cause Itching? - 33 seconds ago
- Could Crestor cause Viral Upper Respiratory Tract Infection? - 35 seconds ago
- Could Valsartan cause Cardiac Failure Congestive? - 38 seconds ago